They assert that when [18F]FDG PET/CT is used in newly diagnosed ER-positive/HER2-negative, breast cancers revealed 4% of unanticipated distant metastases in newly diagnosed in stage I while 14% and 26% were recorded in unanticipated distant metastases in newly diagnosed initial stages II and IIB, respectively [46]. The gene discussed is ERBB2; the disease is breast cancer.